Skip to content
Ejaculation.org

Prospective study · 2015

The Combination of Dapoxetine and Behavioral Treatment Provides Better Results than Dapoxetine Alone in the Management of Patients with Lifelong Premature Ejaculation

Cormio L, Massenio P, La Rocca R, Verze P, Mirone V, Carrieri G (2015). The Combination of Dapoxetine and Behavioral Treatment Provides Better Results than Dapoxetine Alone in the Management of Patients with Lifelong Premature Ejaculation. The Journal of Sexual Medicine. doi:10.1111/jsm.12925

Key finding
In 50 men with lifelong PE followed for 24 weeks, dapoxetine plus sexual behavioural therapy raised mean latency to 370.7 s versus 160.0 s with dapoxetine alone; 80% in the combined group no longer screened positive for PE.

Summary

This open-label prospective study asked whether adding sexual behavioural treatment to on-demand dapoxetine improves results in lifelong premature ejaculation (PE). After a four-week run-in, 50 men were assigned 1:1 to dapoxetine 30 mg alone (25 men) or dapoxetine 30 mg plus behavioural treatment (25 men) for 24 weeks.

Both groups improved significantly, but the combined group improved more. Mean intravaginal ejaculatory latency time (IELT) at 4, 12 and 24 weeks was 84.8, 130.7 and 160.0 seconds with dapoxetine alone, versus 137.9, 232.7 and 370.7 seconds with the combination (baseline 85.0 and 92.0 seconds). At 24 weeks, no man in the dapoxetine-only group reached a Premature Ejaculation Diagnostic Tool score of 8 or less (the range indicating no PE), compared with 80% in the combined group. Side-effect rates were the same (16% in each group).

Limitations

The study was open-label and not described as randomised, so expectations may have influenced results. There was no group receiving behavioural treatment alone, so it cannot show how much behavioural treatment achieves by itself. The sample was small.

What it means for you

Medication and training are not either-or. In this study, men who combined the two improved much more over six months than men who took medication alone. Both groups kept improving, but the combined group improved faster; the study was open-label and not randomised, so treat it as encouraging rather than conclusive.